DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
CGM Market Leade | DexCom, a pioneer in continuous glucose monitoring, faces challenges amid stock volatility while pursuing growth in the evolving diabetes care landscape |
Stelo CGM Launch | Explore DexCom's strategic move into the non-insulin using diabetes market, targeting 125 million potential users with competitive pricing models |
Financial Outlook | Analysts project mid-teens revenue growth despite recent setbacks, with EPS estimates ranging from $1.70 to $2.15 for fiscal years 2024 and 2025 |
Competitive Dynamics | Delve into DexCom's battle for market share against Abbott Laboratories, particularly in DME and AID systems, and its focus on innovation to maintain leadership |
Metrics to compare | DXCM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDXCMPeersSector | |
---|---|---|---|---|
P/E Ratio | 60.4x | −3.8x | −0.7x | |
PEG Ratio | 6.46 | −0.02 | 0.00 | |
Price/Book | 16.6x | 1.9x | 2.6x | |
Price / LTM Sales | 8.6x | 1.6x | 3.1x | |
Upside (Analyst Target) | 12.3% | 46.2% | 47.6% | |
Fair Value Upside | Unlock | 18.6% | 7.7% | Unlock |